Document is current

Article History

Received: 24 June 2024

Accepted: 18 April 2025

First Online: 4 June 2025

Competing interests

: E.A.M. reports compensated service on scientific advisory boards for AstraZeneca, BioNTech, Merck and Moderna; uncompensated service on steering committees for Bristol Myers Squibb and Roche/Genentech; speaker honoraria and travel support from Merck Sharp and Dohme (MSD) and institutional research support from Roche/Genentech (via SU2C grant) and Gilead. E.A.M. also reports research funding from Susan Komen for the Cure for which she serves as a Scientific Advisor, and uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. Z.J.A., E.S.-K., L.M. and S.Y.C. are employees or former employees of Genentech and hold or held shares in Roche. N.H. reports consulting fees from Gilead, Sandoz and Seagen; speaker honoraria from Amgen, AstraZeneca, Daiichi Sankyo, Gilead, Eli Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche and Seagen; honoraria for data safety monitoring board from Roche; and a leadership position at the West German Study Group (minority ownership). H.Z. reports honoraria for advisory/consultancy roles for Roche/Genentech. S.S. reports speaker honoraria from Chugai, Kyowa Kirin, MSD, Novartis, Eisai, Takeda, Daiichi Sankyo, Eli Lilly, AstraZeneca, Pfizer, Taiho, Ono, Nippon Kayaku, Gilead and Exact Sciences; research grants (to institution) from Taiho, Eisai, Chugai, Takeda, MSD, AstraZeneca, Daiichi Sankyo, Gilead, Eli Lilly and Sanofi; honoraria for advisory/consultancy roles for Chugai/Roche, AstraZeneca, Eli Lilly, Pfizer, Kyowa Kirin, Daiichi Sankyo and MSD; and uncompensated leadership roles for the Japan Breast Cancer Research Group, Japanese Society of Medical Oncology and Breast International Group. K.H.J. reports advisory roles for AstraZeneca, Bixink, Everest Medicine, MSD, Novartis, Pfizer, Roche, Takeda Pharmaceuticals and Daiichi Sankyo. A.K. reports advisory roles for Roche, Novartis, Pfizer, Amgen, Daiichi and MSD; a research grant from the German Breast Group and travel/accommodation expenses from Stada. J.S. reports research grants (to institution) from MSD, Roche, Novartis, AstraZeneca, Lilly, Pfizer, GSK, Daiichi Sankyo, Sanofi, Boehringer Ingelheim and Seagen. H.I. reports advisory roles for Chugai, Daiichi Sankyo, AstraZeneca, Lilly and Sanofi; speaker honoraria (personal) from Pfizer and Taiho and speaker honoraria (personal and to institution) from Chugai, Daiichi Sankyo, AstraZeneca, MSD, Amgen, Sanofi, Lilly, Novartis, Bayer, Pfizer, Kyowa Hakko Kirin, Boehringer and Nihon Kayaku. M.L.T. reports research grants (to institution) from Arvinas, AstraZeneca, Bayer, Blueprint Medicines, Genentech/Roche, GlaxoSmithKline, Hummingbird Biosciences, Merck, Novartis, OncoSec Medical and Pfizer; and honoraria for advisory roles from AstraZeneca, Blueprint Medicines, Daiichi Sankyo, Genentech/Roche, Gilead (DSMC), GlaxoSmithKline, G1 Therapeutics (DSMC), Guardant, Merck, Natera, Novartis, Pfizer, RefleXion, Replicate and Sanofi. C.F. reports honoraria from Pfizer, Bayer, Novartis, AstraZeneca, Merck, Roche Canada, Knights Therapeutics and Janssen Oncology; honoraria from Merck, AstraZeneca, Novartis and Roche; speaker’s bureau for Merck, Knight Therapeutics, AstraZeneca and Novartis; expert testimony for Seattle Genetics/Astellas and research funding (to institution) from Astellas Pharma, AstraZeneca, Lilly, Merck, Novartis, Roche/Genentech, Pfizer, Janssen Oncology, Zymeworks, Seattle Genetics and Sermonix Pharmaceuticals. K.P. reports honoraria (to institution) for advisory/consultancy roles from AstraZeneca, Novartis, Roche, Vifor Pharma, Eli Lilly, Pierre Fabre, McCann Health, Roularta, Teva, Gilead Sciences, Pfizer and MSD; personal honoraria for consultancy from Gilead, Novartis, MSD and Roche; personal honoraria for advisory boards from Seagen, AstraZeneca and Pfizer; speaker honoraria (to institution) from Pfizer, Roche, Novartis, Eli Lilly, Mundi Pharma, MSD and Medscape; personal speaker honoraria from Sanofi, AstraZeneca, Exact Sciences, Focus Patient, Pfizer and Gilead Sciences; ownership interest in Need Inc.; funding (to institution) from Sanofi and uncompensated leadership roles for the Belgian Society of Medical Oncology and EORTC Breast Cancer Task Force. A.Q., M.D. and M.L.-H. are employees of F. Hoffmann-La Roche and hold shares in Roche. Y.X. is an employee of Hoffmann-La Roche Ltd and holds shares in Roche. C.H.B. reports research funding (to institution) from Nektar, Pfizer, Polyphor, Amgen, Daiichi Sankyo, Sanofi, Exelixis, Regeneron, Novartis, GSK, Janssen, OBI Pharma, Lilly, Seagen, Roche, BMS, MSD, AstraZeneca, Novocure, Aveo Oncology, Takeda, PharmaMar, Gilead Sciences, Servier, Tolmar, Nanobiotix and Dizal Pharma; clinical research organization funding (to institution) from TRIO, Labcorp, ICON, IQVIA, Parexel, Nuvisan, PSI, Worldwide, Latinaba, Fortrea, PPD and Syneos Health; ownership or stocks in Tummi and MEDSir; advisory boards/presentations/consulting for Gilead, Boehringer Ingelheim, GSK, Novartis, Pfizer, Roche/Genentech, Eisai, Bayer, MSD, AstraZeneca, Zodiac, Lilly, Sanofi and Daiichi and uncompensated leadership roles for the Breast International Group, Latin American Cooperative Oncology Group, ASCO and ESMO. R.H. declares no competing interests.